Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinic... (severe pain due to osteoarthritis of the...)

HOME >> MEDICINE >> TECHNOLOGY

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

Date:9/9/2008

severe pain due to osteoarthritis of the hip or knee. After a screening and washout period from previous treatments (less than or equal to 14 days), patients were administered two periods of treatment with study drugs. Patients were first titrated to effective pain management levels with ALO-01 capsules during open label titration, they were then randomized to double-blind treatment with either ALO-01 capsules or placebo for 12 weeks. Study participants were allowed to use acetaminophen as a rescue medication, up to 500 mg every six hours, as needed.

Efficacy assessments included pain intensity scores on the BPI, recorded in a subject diary and assessed at in-clinic visits.

Safety and tolerability included measurements by rates of self-reported adverse events and a measure of opioid withdrawal, an indication of naltrexone leakage from the capsules, called clinical opiate withdrawal scores (COWS). ALO-01 capsules were safe and well-tolerated in this study, with an overall safety profile consistent with that of other opioid products. COWS data suggest that naltrexone did not leak out of the capsules, and there was no increased risk of opioid withdrawal versus placebo. Adverse events were mostly mild to moderate. The most common adverse events during titration with ALO-01 were constipation (30.5 percent) and nausea (21.0 percent); during the 12-week maintenance phase the adverse events were diarrhea (12.3 percent and 12.1 percent) and nausea (11.7 percent and 7.5 percent) for ALO-01 and placebo groups, respectively.

Forward-Looking Statements

Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other important potential risks
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

Post Your Comments:

(Date:5/23/2013)... 23, 2013 The need to add tissue ... was highlighted prominently at the 108 th ... in San Diego. According to SonaCare Medical, a ... (HIFU) technology, the need for image-guided technologies to ... to consider minimally invasive ablative treatments, was addressed ...

(Date:5/23/2013)... Mass. , May 23, 2013 Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...

(Date:5/23/2013)... , May 23, 2013 Net Medical Xpress Solutions, ... market, announced today the company has signed a letter ... company based in Huntsville, AL . ... in the staffing and recruitment of telemedicine physicians. Consideration ... the final agreement, which is expected by June 30, ...

Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6 First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2 First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3 First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4 Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2 Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3

[0] Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting [0] First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection [0] Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company

... BOSTON, Dec. 23, 2010 Scientists at the University ... key immune cells that combat allergies and autoimmune diseases. ... issue of the journal Science, and technology ... Vedanta Biosciences. Dr. Kenya Honda and ...

... Dec. 23, 2010 Par Pharmaceutical Companies, Inc. (NYSE: ... Executive Officer, Patrick G. LePore, will present an overview of ... Wednesday, January 12, 2011 from 8:30 to 9:00am PST (11:30am ... Conference at the Westin St. Francis Hotel, San Francisco, California. ...

Cached Medicine Technology:'Good Clostridia' in the Gut Protect from Allergy and Autoimmunity 2 'Good Clostridia' in the Gut Protect from Allergy and Autoimmunity 3

'Good Clostridia' in the Gut Protect from Allergy and Autoimmunity Par Pharmaceutical Companies to Present 2011-2013 Outlook at the J.P. Morgan Healthcare Conference

(Date:5/25/2013)... Many viruses and parasites that affect both dogs and ... illness than can result in liver or kidney failure ... a veterinarian. These germs could be found ... Dr. Susan Nelson, a clinical associate professor at Kansas ... diseases can be fatal, even with treatment," she said ...

(Date:5/25/2013)... TX (PRWEB) May 25, 2013 Studies ... those who are carrying excessive weight and their inability ... for many, simply losing weight can naturally relieve many ... found that improvement in sleep quality was significantly associated ... six month study dated November 6th, 2012, ...

(Date:5/25/2013)... York, New York (PRWEB) May 25, 2013 ... who allegedly suffered serious, life-threatening episodes of internal bleeding while ... litigation underway in U.S. District Court, Southern District of Illinois, ... the Court’s website, 818 Pradaxa side effect claims had ... 2013. That’s up from 705 claims reported by the ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 According ... Emergency Management Market, 2013–2018", published by MarketsandMarkets is ... a CARC of 5.54% which analyzes and studies ... North America, Europe, Asia, and Rest of the ... Market Data Tables , 87 Figures ...

(Date:5/25/2013)... 25, 2013 Acuity Games ’ innovative ... version of Word Hunt is available today, expanding ... Edge Match, Flash 2, Sudoku and Matchematics will roll out ... gameplay and revolutionary lifetime brain fitness measurement have been re-optimized ... “100 years of brain fitness measurement in your pocket. ...

Breaking Medicine News(10 mins):Health News:Hidden Dangers Dog Dog Parks 2 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2 Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2 Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4 Health News:Acuity Games Apps Come to the iPhone 2

[0] Hidden Dangers Dog Dog Parks [0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep [0] Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports [0] Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets [0] Acuity Games Apps Come to the iPhone

... President,and CEO of America,s Health Insurance Plans, today ... ), "Today,s announcement presents an opportunity to ... rising health care costs in America., "At ... soar above inflation,every year, health insurance plans, tools ...

... Parenthood TV Ad For Containing,Inappropriate, Content While Original ... 13 "It is outrageous that,YouTube would black-out ... sex video while it continues to carry the ... of American Life League., The "inappropriate nature" ...

... replicated in larger study, experts caution , , WEDNESDAY, Feb. ... combat cancer that is now being used to treat ... also work against a common form of multiple sclerosis. ... issue of the New England Journal of Medicine ...

... SEGUNDO, Calif., Feb. 13 DaVita Inc.,(NYSE: DVA ... ended December,31, 2007. Net income for the three months ... share, as compared to $74.1 million, or $0.70 per,share, ... http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ), Net income for the year ended ...

... Eight outstanding cancer care providers from a variety of ... 2008 American Cancer Society Lane W. Adams Quality of ... The Lane W. Adams Quality of Life Award recognizes ... and consistent excellence in providing compassionate, skilled care, and ...

... COEUR D,ALENE, Idaho, Feb. 13 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... groups across the United States, today announced,financial results for its ... 2007 Highlights, -- Full year revenues grew 65% to ... the full-year 2006. Organic revenue grew $21.4 million, or 23% ...

AHIP Statement on New York Attorney General's Announcement ICYMI: YouTube Censors American Life League Cancer Drug Works Against MS in Early Trial DaVita 4th Quarter 2007 Results American Cancer Society honors exemplary cancer caregivers NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Isopropanol (Includes Acetone)Isofedrol Isoenzymes, Amylase Islet Cell Antigen (ICA) 512